8A: Overview: Economic & Company Trends
The U.S. economy is navigating a complex transition, marked by robust growth and falling inflation, yet shadowed by persistent consumer unease.
We observe a rare combination of strong Real GDP growth at 4.40% and a healthy labor market with unemployment at 4.30%, both above historical averages. Simultaneously, inflation, measured by CPI, has cooled to 2.6%, falling from its peaks. However, interest rates remain elevated, with the 10-Year Treasury at 4.15% and the Fed Funds Rate at 3.64%, even as both show a falling trend. The stark contrast lies in consumer sentiment, which at 52.9, remains deeply pessimistic, ranking in the 4th percentile historically.
- The recent easing in the Effective Fed Funds Rate to 3.64% (70th percentile, falling) and the 10-Year Treasury to 4.15% (82nd percentile, falling) signals a potential pivot in monetary policy. While still above historical averages, this trend offers a future tailwind for corporate financing and capital allocation, potentially reducing the cost of debt for companies like Amgen.
- Inflation cooling, with CPI at 2.6% and Core CPI at 2.7% (both below their historical averages and trending stable/falling), suggests price stability is returning without a severe economic slowdown. This alleviates pressure on input costs and preserves consumer purchasing power, which is broadly favorable for healthcare spending.
- Despite robust Real GDP growth of 4.40% (79th percentile) and a low unemployment rate of 4.30% (55th percentile), consumer sentiment lingers at a concerning 52.9, placing it in the 4th percentile historically. This divergence indicates that while economic fundamentals are strong, a psychological overhang persists, which could indirectly influence discretionary healthcare choices, even for essential products.
For Amgen Inc. (AMGN), this environment presents a mixed picture. The overall economic strength and contained inflation are generally supportive, contributing to Amgen's impressive +21.1% revenue growth and expanding 39.8% operating margin. However, the elevated cost of capital, despite falling trends, could still impact future investment decisions for R&D or M&A, while the significant -78.2% drop in free cash flow growth warrants close attention from an operational efficiency perspective.
Overall Trajectory: The current macro environment is characterized by a strong, disinflationary growth trajectory, with the caveat of deeply pessimistic consumer sentiment and a potential easing of monetary policy.
The charts below trace how these macroeconomic forces have evolved and how Amgen has navigated them, providing deeper context to its financial performance.
Economic Environment
| Indicator | Current | Historical Avg | Percentile | Trend |
|---|---|---|---|---|
| Effective Fed Funds Rate | 3.64% | 2.03% | 70th | ↓ Falling |
| 10-Year Treasury | 4.15% | 2.67% | 82th | ↓ Falling |
| 2-Year Treasury | 3.57% | 2.19% | 71th | → Stable |
| 30-Year Mortgage Rate | 6.00% | 4.72% | 68th | → Stable |
| CPI (All Items) YoY | 2.6% | 3.1% | 53th | ↓ Falling |
| Core CPI YoY | 2.7% | 3.1% | 52th | → Stable |
| Real GDP Growth | 4.40% | 2.71% | 79th | ↑ Rising |
| Unemployment Rate | 4.30% | 4.64% | 55th | ↓ Falling |
| Consumer Sentiment | 52.9 | 80.9 | 4th | → Stable |
Company Fundamentals
Stock Performance
Data period: 2015-01 to 2026-03
8B: Macro Sensitivity & Exposure Analysis
Understanding how a company's financial performance responds to broad macroeconomic shifts is crucial for institutional investors. This analysis dissects the macro sensitivities of Amgen Inc., revealing how its revenue growth interacts with key economic indicators, providing a clearer picture for portfolio positioning and risk management.
We regressed quarterly revenue growth against macro indicators over a period spanning 2016Q1 to 2025Q4, utilizing a Ridge Regression model with 16-quarter rolling windows to assess coefficient stability and consistency.
AMGN
Amgen exhibits a defensive yet nuanced macro profile, thriving in stable, higher-inflation environments but facing headwinds from rising rates and improving consumer sentiment.
Amgen's macro DNA is complex, reflecting its position as a pharmaceutical giant with high pricing power (gross margin 76.10%) and significant leverage (debt-to-equity 6.31). While largely non-cyclical, its revenue growth shows a distinct preference for stable, higher-inflationary periods (CPI level β=+0.4886) and, surprisingly, even higher interest rate environments (rates level β=+0.4503) once those levels are established. However, the *transition* to higher rates is a clear detriment, consistent with its leveraged capital structure.
- Inflation Sensitivity: Amgen demonstrates a high positive sensitivity to the *level* of inflation (CPI level β=+0.4886, moderate confidence). This suggests the company performs better in sustained high-inflation environments, likely due to its strong pricing power, enabling it to pass through rising costs and maintain margins. Conversely, it is mildly hurt when inflation is *rising* (CPI change β=-0.0584, stable confidence), indicating a potential lag in adjustment.
- Interest Rate Sensitivity: The company exhibits a high, mixed exposure to interest rates. Revenue growth is significantly hurt when interest rates are *rising* (rates change β=-0.3178, stable confidence), a clear consequence of its high leverage (D/E=6.31) which increases debt servicing costs and impacts the present value of future cash flows. However, paradoxically, Amgen performs better in environments with *high* interest rate levels (rates level β=+0.4503, moderate confidence), suggesting that once rates stabilize at an elevated level, the business can adapt, or perhaps such environments correlate with robust healthcare spending.
- Mortgage Rate Sensitivity: Mirroring its general rate exposure, Amgen's revenue growth is moderately hurt when mortgage rates are *rising* (mortgage change β=-0.2394, stable confidence). This could reflect indirect impacts on consumer discretionary spending or broader economic sentiment, although its primary business is less directly tied to housing. Similar to general rates, it performs better in high mortgage rate environments (mortgage level β=+0.3925, moderate confidence).
- Consumer Sentiment Sensitivity: Notably, Amgen shows a high negative sensitivity to the *level* of consumer sentiment (consumer level β=-0.2983, moderate confidence). This counter-cyclical characteristic suggests that its revenue growth is stronger when consumer sentiment is lower, positioning it as a defensive play that may be prioritized during periods of economic uncertainty or caution. Rising consumer sentiment also mildly hurts revenue (consumer change β=-0.0685, moderate confidence).
- Economic Growth (GDP) Sensitivity: Consistent with its low cyclicality (score 33.90%), Amgen shows low and largely neutral sensitivity to GDP levels (GDP level β=+0.0382, moderate confidence). There's a slight benefit when GDP is rising (GDP change β=+0.0634, moderate confidence), but overall, it's not a primary driver.
- Unemployment Rate Sensitivity: Amgen performs marginally better in environments with *high* unemployment rates (unemployment level β=+0.0835, stable confidence). This further reinforces its defensive characteristics, as healthcare demand tends to be less elastic even during periods of economic stress and job losses.
In a rising interest rate environment, Amgen is likely to face headwinds to revenue growth due to increased borrowing costs. However, if inflation and interest rates stabilize at higher levels, the company's pricing power and defensive characteristics could allow it to perform relatively well. A significant improvement in consumer sentiment, paradoxically, may signal a tougher environment for Amgen's revenue growth.
- Rapidly rising interest rates (rates change β=-0.3178) could pressure revenue growth due to increased financing costs and reduced present value of future earnings.
- A sustained period of falling inflation or disinflation (CPI level β=+0.4886) could erode a key tailwind for revenue growth.
- Significant and sustained increases in consumer sentiment (consumer level β=-0.2983) could indicate an environment less favorable to Amgen's defensive positioning.
- A stable, higher-inflation environment (CPI level β=+0.4886) allows Amgen to leverage its strong pricing power for revenue growth.
- Periods of economic uncertainty or lower consumer sentiment (consumer level β=-0.2983) tend to be more favorable for Amgen's revenue growth.
- If interest rates stabilize at elevated levels, rather than continuing to rise, the negative 'change' impact subsides, allowing the 'level' benefit (rates level β=+0.4503) to potentially manifest.
Amgen stands out as a defensive play with a peculiar sensitivity profile. Unlike many companies that struggle universally with high rates, Amgen appears to adapt to high-rate *levels* while being vulnerable to *rising* rates. Its inverse relationship with consumer sentiment further solidifies its role as a potential hedge against broader economic optimism, making it a distinct choice for investors seeking stability in uncertain times.
While several key 'change' exposures, such as those for rates and mortgage, show strong sign stability (>85%), some 'level' exposures exhibit moderate confidence (57-67%), suggesting these relationships, while present, have shown some variability across the rolling windows.
Investors should consider Amgen as a defensive anchor, particularly effective in environments characterized by stable, higher inflation and economic caution. While vulnerable to the *pace* of rate hikes, its ability to navigate high-rate *levels* and its inverse correlation with consumer sentiment offer unique portfolio diversification benefits. Positioning for stable, higher-rate and inflation regimes, rather than rapidly tightening ones, aligns well with Amgen's macro sensitivities.
Methodology
Revenue_Growth_t = α + β₁(Macro_Level_t) + β₂(Macro_Change_t) + ε
Model specification: - Y = Company revenue growth (quarterly) - Macro_Level = Absolute value of macro variable (e.g., Fed Funds at 5%) - Macro_Change = Quarter-over-quarter change in macro variable - Separate regressions for each macro variable to isolate effects - Ridge regularization (α=1.0) to handle multicollinearity Sign stability is computed by running the regression on rolling 20-quarter windows and counting the fraction of windows with the same coefficient sign.
- High: |β| > 0.3
- Moderate: |β| > 0.1
- Low: |β| ≤ 0.1
- Stable: Sign stability > 75%
- Moderate: Sign stability > 50%
- Unstable: Sign stability ≤ 50%
AMGN - Amgen Inc.
Sample of the data used for regression analysis. Company fundamentals aligned with macro indicators by quarter.
| Fiscal Quarter | Revenue Growth (YoY %) | Gross Margin (%) |
|---|---|---|
| 2016Q1 | 9.8% | 81.6% |
| 2016Q2 | 5.9% | 81.5% |
| 2016Q3 | 1.5% | 82.3% |
| ... | ... | ... |
| 2025Q2 | 9.3% | 67.2% |
| 2025Q3 | 12.4% | 67.8% |
| 2025Q4 | 8.6% | 81.9% |
Ridge regression coefficients (β) showing sensitivity to each macro variable. Separate columns for Level (absolute value) and Change (direction).
| Variable | β (Level) | β (Change) | Sign Stability (L) | Sign Stability (C) |
|---|---|---|---|---|
| CPI | 0.489 | -0.058 | 57% | 86% |
| RATES | 0.450 | -0.318 | 57% | 86% |
| MORTGAGE | 0.393 | -0.239 | 57% | 86% |
| CONSUMER | -0.298 | -0.069 | 57% | 57% |
| GDP | 0.038 | 0.063 | 67% | 67% |
| UNEMPLOYMENT | 0.084 | 0.025 | 86% | 57% |
* p<0.10, ** p<0.05, *** p<0.01 | Sign Stability = fraction of rolling windows with same coefficient sign
How we applied thresholds to convert regression coefficients into classifications.
| Variable | Type | β | → Direction | → Strength | → Confidence |
|---|---|---|---|---|---|
| CPI | Level | 0.489 | Positive | High | Moderate |
| CPI | Change | -0.058 | Negative | Low | Stable |
| RATES | Level | 0.450 | Positive | High | Moderate |
| RATES | Change | -0.318 | Negative | High | Stable |
| MORTGAGE | Level | 0.393 | Positive | High | Moderate |
| MORTGAGE | Change | -0.239 | Negative | Moderate | Stable |
| CONSUMER | Level | -0.298 | Negative | High | Moderate |
| CONSUMER | Change | -0.069 | Negative | Low | Moderate |
| GDP | Level | 0.038 | Neutral | Low | Moderate |
| GDP | Change | 0.063 | Positive | Low | Moderate |
| UNEMPLOYMENT | Level | 0.084 | Positive | Low | Stable |
| UNEMPLOYMENT | Change | 0.025 | Neutral | Low | Moderate |
Company characteristics that inform macro sensitivity expectations:
| Trait | Classification | Key Metric | Implication |
|---|---|---|---|
| Pricing Power | High | GM: 76.1% | Can pass through inflation |
| Leverage | High | D/E: 6.31 | Rate sensitive |
| Macro Variable | Direction | Strength | Confidence | Interpretation |
|---|---|---|---|---|
| CPI | ↑ Positive | High | Moderate | High positive cpi exposure |
| RATES | ↔ Mixed | High | Moderate | High mixed rates exposure |
| MORTGAGE | — Neutral | High | Moderate | High neutral mortgage exposure |
| CONSUMER | ↓ Negative | High | Moderate | High negative consumer exposure |
| GDP | ↑ Positive | Low | Moderate | Low positive gdp exposure |
| UNEMPLOYMENT | ↑ Positive | Moderate | Moderate | Moderate positive unemployment exposure |
Level: Performance in high-X environments | Change: Performance when X is rising
| Variable | Level Sensitivity | Change Sensitivity |
|---|---|---|
| CPI |
Positive (high)
Performs better in high-inflation environments (high)
|
Negative (low)
Hurt when inflation rises (low)
|
| RATES |
Positive (high)
Performs better in high-interest rate environments (high)
|
Negative (high)
Hurt when interest rates rise (high)
|
| GDP |
Neutral
No significant sensitivity to GDP levels
|
Positive (low)
Benefits when GDP rises (low)
|
| UNEMPLOYMENT |
Positive (low)
Performs better in high-unemployment environments (low)
|
Neutral
No significant sensitivity to unemployment changes
|
- Cpi falling
- Consumer rising
- Unemployment falling
- Cpi rising
- Consumer falling
- Unemployment rising
Summary: AMGN is positively exposed to inflation and negatively exposed to consumer. Key risks: cpi decreases, consumer increases.
Method: Mixed | Data: 44 quarters (2015Q1-2025Q4)
8C: Macro Shock / Event Response
Methodology: Event Study with Bootstrap Inference
We analyze stock returns around macroeconomic announcements using bootstrap confidence intervals for the median. This approach is robust to outliers and makes no distributional assumptions.
Median is robust to extreme outliers. A single +10% or -10% day won't distort the central tendency.
Resample data 1000x, compute median each time, take percentiles. No normality assumption required.
If CI excludes zero → evidence of consistent directional pattern.
If CI includes zero → no reliable pattern detected.
When central bankers speak or key economic indicators hit the wires, financial markets often react sharply. But the impact isn't uniform; different companies respond in unique ways, reflecting their business models and sensitivities to macro factors. Our event study delves into how specific companies, like Amgen Inc., have historically navigated these pivotal macroeconomic announcements.
We analyzed daily returns around 437 macro events for Amgen Inc. between 2015 and 2026, using bootstrap confidence intervals to identify reliable patterns in stock price movements.
Across the broader market analysis, Non-Farm Payrolls (NFP) consistently elicited the most significant directional responses, while CPI and FOMC events showed more mixed reactions.
Key Findings Across All Companies:Our aggregate analysis, encompassing 437 macro events, reveals that employment data, particularly NFP, tends to be a more potent market mover than inflation or monetary policy announcements on average. GDP announcements also showed a slight positive bias, though less reliably.
- **NFP: A Reliable Catalyst.** Non-Farm Payrolls announcements consistently drove market reactions, with a median return of +0.3265% (95% CI: +0.0758% to +0.5312%). This positive bias is statistically significant as its confidence interval excludes zero, indicating that strong employment data generally translates to immediate market optimism. A notable 60.14% of NFP days saw positive returns.
- **CPI & FOMC: Muted Direction.** Both Consumer Price Index (CPI) releases and Federal Open Market Committee (FOMC) announcements, despite their importance, showed no statistically significant directional impact on the market overall. For CPI, the median return was -0.08875% (95% CI: -0.3833% to +0.4132%), while FOMC days saw a median of -0.0518% (95% CI: -0.2435% to +0.1305%). In both cases, the confidence intervals include zero, suggesting a lack of a consistent positive or negative bias, with reactions being nearly evenly split (CPI: 47.14% positive; FOMC: 48.35% positive).
AMGN
Amgen Inc. exhibits a statistically significant positive bias on Non-Farm Payrolls days, reflecting its sensitivity to broader economic health, while other macro events produce less consistent immediate directional moves.
As a large-cap biotechnology firm, Amgen's operational performance is generally less directly tied to day-to-day economic fluctuations than cyclical industries. However, its stock price reacts to shifts in overall market sentiment and investor risk appetite, which are often influenced by major economic data. Our analysis shows that while most macro events don't elicit a strong, consistent directional response, employment data stands out as a reliable positive catalyst for AMGN.
For Amgen, the initial positive reaction to NFP announcements tends to persist, with a 6-month momentum rate of 58.46%. This suggests that the market's initial assessment of employment data's impact on broader economic health, and by extension, on Amgen, often holds true over the medium term. Conversely, for CPI events, a reversal pattern is more common (62.5% reversal rate), hinting that initial reactions to inflation data might be overblown or quickly corrected.
- **NFP: A Clear Positive Signal.** Amgen's stock reliably trends upwards on Non-Farm Payrolls release days, posting a median return of +0.3265% (95% CI: +0.0758% to +0.5312%). The confidence interval excludes zero, providing robust statistical evidence of this positive bias. This suggests that strong employment figures, signaling a healthy economy and potentially greater healthcare spending capacity, are generally perceived as beneficial for Amgen, with 60.14% of NFP events resulting in positive returns.
- **CPI: Initial Jitters Often Reverse.** While CPI announcements trigger a slight median negative response of -0.08875% for AMGN, this reaction is not statistically significant (95% CI: -0.3833% to +0.4132%). More notably, the initial market move on CPI days has a tendency to reverse over the subsequent six months, with a 62.5% reversal rate. This could imply that investors initially overreact to inflation data, and a more considered view prevails over time for Amgen.
- **FOMC & GDP: Largely Ambiguous.** Both FOMC interest rate decisions and GDP growth rate releases do not show a statistically reliable directional impact on Amgen's stock. FOMC days registered a median return of -0.0518% (95% CI: -0.2435% to +0.1305%), while GDP days saw a median of +0.0788% (95% CI: -0.1826% to +0.3559%). In both cases, the confidence intervals include zero, indicating that while individual events can cause movement, there's no consistent pattern, with returns split roughly 50/50 between positive and negative outcomes.
- **Earnings: Limited Data, Strong Momentum.** With only 5 earnings events in our analysis, the median return of -0.1472% is highly uncertain (95% CI: -1.7669% to +0.3665%). However, for the 4 events with 6-month follow-up, 75.0% showed momentum, suggesting that when earnings do move the stock, the direction tends to persist. It's crucial to acknowledge the very small sample size here, limiting the reliability of this observation.
The histograms below, not explicitly provided but implied by our analysis, would further illustrate the full distribution of returns—revealing not just averages, but the range of outcomes investors have experienced around these critical macro events.
These patterns reflect historical tendencies and are not guarantees of future performance. Market dynamics evolve, and past reactions may not persist in different economic regimes or under novel circumstances. Additionally, correlation does not imply causation, as numerous factors influence stock prices on any given day.
For investors in Amgen, Non-Farm Payrolls announcements have historically presented a reliably positive catalyst, with initial reactions tending to persist. While other macro events like CPI and FOMC decisions generate volatility, they lack consistent directional impact on AMGN. This suggests that while monitoring all macro data is prudent, NFP days might be particularly relevant for observing market sentiment towards large-cap biotech, potentially offering insights into broader economic health and its indirect implications for healthcare spending and innovation.
Aggregate Event Responses (All Companies)
Note on Aggregation: The aggregate statistics pool all individual stock returns on event days without weighting. Each stock-event observation is treated equally. For portfolio-level inference, consider applying appropriate weights based on your holdings. S&P 500 benchmark is included for market-wide comparison.
Median daily return on event days, with 95% bootstrap confidence intervals. S&P 500 shown as market benchmark.
| Event Type | N Events | Portfolio Median | S&P 500 Median | 95% CI (Portfolio) | % Positive | Significance |
|---|---|---|---|---|---|---|
| FOMC | 91 | -0.05% | -0.02% | [-0.24%, +0.13%] | 48% | CI includes zero |
| CPI | 70 | -0.09% | +0.25% | [-0.38%, +0.41%] | 47% | CI includes zero |
| NFP | 143 | +0.33% | +0.18% | [+0.08%, +0.53%] | 60% | CI excludes zero |
| GDP | 133 | +0.08% | +0.16% | [-0.18%, +0.36%] | 54% | CI includes zero |
N=91 events
N=70 events
N=143 events
N=133 events
Company-Specific Event Responses
AMGN - Amgen Inc.
Data: 2015-01-05 to 2026-03-11 (2812 trading days) | Most reactive to: NFP
| Event | N | Median | 95% CI | % Positive | Pattern |
|---|---|---|---|---|---|
| FOMC | 91 | -0.05% | [-0.24%, +0.13%] | 48% | No clear pattern |
| CPI | 70 | -0.09% | [-0.38%, +0.41%] | 47% | No clear pattern |
| NFP | 143 | +0.33% | [+0.08%, +0.53%] | 60% | Positive pattern |
| GDP | 133 | +0.08% | [-0.18%, +0.36%] | 54% | No clear pattern |
| Earnings | 5 | -0.15% | [-1.77%, +0.37%] | 40% | No clear pattern |
Compares event-day reaction to 6-month subsequent return. Momentum: same direction as event-day. Reversal: opposite direction.
| Event | Events w/ 6M Data | Avg 6M Return | Momentum | Reversal | Dominant Pattern |
|---|---|---|---|---|---|
| FOMC | 86 | +5.6% | 44 (51%) | 42 (49%) | Mixed |
| CPI | 56 | +7.4% | 21 (38%) | 35 (62%) | Reversal |
| NFP | 130 | +5.8% | 76 (58%) | 54 (42%) | Mixed |
| GDP | 124 | +5.3% | 58 (47%) | 66 (53%) | Mixed |
| Earnings | 4 | +8.6% | 3 (75%) | 1 (25%) | Momentum |
N=91
N=70
N=143
N=133
N=5
FOMC: Median: -0.05% (95% CI: -0.24% to +0.13%), N=91; Earnings: Median: -0.15% (95% CI: -1.77% to +0.37%), N=5
8D: Regime, Cycle & State-Dependent Behavior
Current Macro Regime
Rate policy: Easing (4mo) | Inflation: Moderate (CPI: 2.4%) | Growth: Expansion | Consumer: Pessimistic | Cycle: Early Expansion
Not all companies dance to the same macro tune. Some thrive when rates are cut; others need inflation to run hot. Understanding a company's unique 'regime fingerprint' is crucial for institutional investors looking to strategically position portfolios, especially as macroeconomic landscapes continue to evolve. This analysis delves into how Amgen's performance correlates with distinct interest rate, inflation, and business cycle regimes.
As of February 1, 2026, the macroeconomic landscape is defined by an Easing rate regime, with the Fed Funds rate at 3.64% following a -0.69% cut over the past six months. Inflation sits in the Moderate band at 2.40% YoY CPI, while economic growth remains robust in an Expansion phase with GDP at 4.4%. Consumer sentiment, however, is Pessimistic at 52.9, creating a nuanced backdrop as we navigate the Early Expansion phase of the business cycle.
AMGN
Amgen demonstrates a clear preference for easing monetary conditions and higher, but not runaway, inflation, thriving particularly in the early stages of economic recovery.
Amgen's performance shows a distinct sensitivity to monetary policy, historically delivering its strongest returns in Easing rate regimes, averaging an impressive +2.34%/month with a volatility of 8.25%. This contrasts sharply with its weakest showing in Stable rate periods, where it delivered a mere +0.46%/month (7.04% volatility), creating a significant performance spread of 1.87%. On the inflation front, Amgen thrives in 'Elevated' environments (CPI 3-4%), returning +2.86%/month, but struggles considerably when inflation becomes 'High' (>4%), where returns plummet to just +0.03%/month. This suggests Amgen benefits from a healthy inflationary backdrop that isn't spiraling out of control.
Amgen's ideal macro cocktail is a blend of Easing rates, Elevated inflation, and a Contraction phase, reflecting a potential 'flight to quality' or defensive growth appeal during downturns when rates are being cut. Conversely, its most challenging environment is characterized by Stable rates, High Inflation, and an economic Slowdown.
Given the current state of Easing rates, Moderate inflation, and Early Expansion, Amgen's current environment rating is 'Neutral.' While the Easing rate regime and Early Expansion cycle are favorable tailwinds, the Moderate inflation (CPI: 2.4%) is not its absolute best 'Elevated' environment, and the Pessimistic consumer sentiment could exert some pressure, balancing the overall outlook.
Amgen exhibits significant state-dependent behavior, with its monthly returns varying widely across different rate and inflation regimes, indicating it is not a 'set-and-forget' investment through all macro cycles.
The current business cycle is in an Early Expansion phase. For Amgen, this is historically its strongest phase, averaging a robust +7.9%/qtr. This suggests that the company is well-positioned for the current stage of economic recovery, potentially benefiting from renewed healthcare spending or investor confidence in defensive growth names.
Amgen's substantial performance spreads—1.87% between its best and worst rate regimes, and 2.83% across inflation regimes—underscore its sensitivity to macro conditions. While often perceived as a defensive pharmaceutical giant, these figures reveal that Amgen is far from immune to the prevailing economic winds, showing distinct preferences rather than consistent outperformance across all environments.
Should the Fed continue its Easing policy, Amgen stands to benefit significantly, aligning with its historical outperformance in such regimes. However, a re-acceleration into a 'High Inflation' environment, or a prolonged 'Stable' rate period, could challenge its returns. Monitoring the duration of the current Easing cycle (currently 4 months) and inflation trends will be key to gauging future performance.
For institutional investors, Amgen represents a growth-oriented pharmaceutical play with clear macro sensitivities. Its strong historical performance in Easing rate cycles and Early Expansion phases suggests it could be a strategic holding in the current environment, provided inflation remains contained within the 'Moderate' or 'Elevated' bands. Investors should be mindful of shifts to 'Stable' rates or 'High Inflation' as potential headwinds, which could erode returns.
Regime Classification Methodology
We classify macro regimes using transparent, rules-based thresholds applied to historical data.
- Tightening: >+25% 6mo change
- Easing: <-25% 6mo change
- High: >4% CPI YoY
- Elevated: 2-4% CPI YoY
- Moderate: 2-3% CPI YoY
- Low: <2% CPI YoY
- Expansion: >2% GDP
- Slowdown: 0-2% GDP
- Contraction: <0% GDP
- Confident: >85 UMCSENT
- Neutral: 70-85 UMCSENT
- Cautious: 55-70 UMCSENT
- Pessimistic: <55 UMCSENT
Performance by Macro Regime
Current regime: Moderate
Current regime: Expansion
Current phase: Early Expansion
Company Regime Profiles
AMGN - Amgen Inc.
| Regime | Months | Avg Return | Volatility | % Positive |
|---|---|---|---|---|
| Stable ⬇ | 58 | +0.46%/mo | 7.04% | 53% |
| Tightening | 44 | +1.53%/mo | 6.47% | 57% |
| Easing ⬆ | 26 | +2.34%/mo | 8.25% | 62% |
Performance spread (best - worst): 1.87%/mo
| Phase | Quarters | Avg Quarterly Return |
|---|---|---|
| Early Expansion ⬆ NOW | 5 | +7.9%/qtr |
| Mid Expansion ⬇ | 29 | +2.2%/qtr |
| Late Expansion | 5 | +3.9%/qtr |
| Contraction | 4 | +7.3%/qtr |
- Rate sensitivity: Performs best in Easing (+2.34%/mo), worst in Stable (+0.46%/mo)
- Inflation impact: Favors elevated environments
- Cycle positioning: Historically strongest in Early Expansion
Analysis period: 2015-01 to 2026-02 | Quarters analyzed: 44
8E: Cross-Sectional & Peer Comparison
Understanding a company's macroeconomic sensitivities in isolation provides only part of the picture. True insight emerges when evaluating these exposures relative to its industry peers, revealing unique risk-reward profiles and differentiating factors that inform strategic positioning within a sector.
AMGN
AMGN stands out in the healthcare sector with a significant positive rate sensitivity of +0.45, starkly contrasting its peer average of -0.07, and an elevated inflation sensitivity of +0.49, well above the peer average of +0.13.
AMGN exhibits high positive sensitivity to both interest rates (+0.45) and inflation (+0.49), placing it significantly above the typical healthcare peer. For context, the average peer shows a slight negative rate sensitivity (-0.07) and only moderate positive inflation sensitivity (+0.13). Its GDP sensitivity of +0.04 and beta of 0.47 are broadly in line with the peer average of +0.10 and 0.45, respectively, indicating its macro story is primarily driven by rate and inflation dynamics.
These pronounced sensitivities can be largely attributed to AMGN's substantial leverage of 6.31, dramatically higher than the peer average of 0.13. While healthcare is generally seen as defensive, AMGN's debt structure means higher rates can impact financing costs, yet its positive sensitivity suggests that its revenue streams or pricing power benefit from economic conditions that might also drive rates and inflation higher. This could stem from its specific product mix, pricing strategies, or payer dynamics that allow it to pass on costs or benefit from higher nominal spending.
For investors, AMGN represents a unique exposure within healthcare. In an environment of rising rates and persistent inflation, AMGN is positioned to potentially outperform its less sensitive peers, offering a hedge against these macro trends, albeit with the inherent risks of its elevated debt load. Conversely, a disinflationary or rate-cutting cycle could present headwinds not seen by many of its industry counterparts.
AMGN's macro profile is distinctly differentiated by its high positive sensitivities to both interest rates and inflation, a significant departure from its more defensively positioned healthcare peers. This makes AMGN a compelling option for investors seeking specific macro exposure within the often-homogenous healthcare sector, particularly in environments characterized by rising nominal growth and inflation.
AMGN vs Peers
Healthcare | 8 peers analyzed
| Company | Rate Sens. | Inflation Sens. | GDP Sens. | Beta | Leverage |
|---|---|---|---|---|---|
| AMGN | +0.45 | +0.49 | +0.04 | 0.47 | 6.31 |
| GILD | +0.04 | +0.35 | +0.31 | 0.37 | 0.00 |
| PFE | -0.36 | +0.01 | +0.07 | 0.41 | 0.00 |
| SNY | -0.05 | +0.09 | +0.02 | 0.36 | 0.28 |
| MRK | -0.08 | +0.12 | +0.02 | 0.26 | 0.00 |
| DHR | -0.49 | -0.07 | +0.16 | 0.96 | 0.35 |
| BMY | -0.48 | -0.39 | +0.00 | 0.29 | -0.81 |
| NVO | +0.58 | +0.63 | -0.03 | 0.27 | 0.67 |
| BSX | +0.26 | +0.33 | +0.28 | 0.70 | 0.51 |
| Peer Average | -0.07 | +0.13 | +0.10 | 0.45 | 0.13 |
Sensitivity values are regression coefficients. Negative rate sensitivity = hurt by rising rates. Positive inflation sensitivity = benefits from inflation.
Positioning vs Peers
AMGN
Peers analyzed: 8 | Peers with sufficient data: 8
8F: Macro & Fundamental Time Patterns
Data Summary
- Found 4 significant macro-fundamental relationships (|r| >= 0.25).
Understanding the precise timing of macroeconomic impacts is critical for institutional investors to optimize portfolio positioning and risk management. This analysis delves into the lead-lag relationships between key macroeconomic variables and company fundamentals, offering insights into how quickly, or slowly, external forces translate into corporate performance and what that means for investment strategy.
AMGN
Amgen exhibits a dual timing profile, acting as a leading indicator for GDP and unemployment while showing a significant lag in response to interest rates and inflation.
AMGN's fundamentals show a notable 6-quarter lag in response to both interest rate changes (correlation +0.69) and CPI inflation (correlation +0.53), suggesting these macro shifts take considerable time to manifest. Conversely, AMGN's performance can precede broader economic shifts, acting as a leading indicator for GDP and unemployment with a -1Q lag. Specifically, its fundamentals tend to strengthen just prior to economic slowdowns (negative correlation of -0.26 with GDP) and before increases in unemployment (positive correlation of +0.31 with unemployment).
This unique profile aligns with a defensive, counter-cyclical business model. As a major biotechnology firm, demand for AMGN's essential medicines and treatments often proves resilient during economic contractions, potentially even seeing increased uptake as other sectors falter. The long R&D cycles and stable demand for its specialized products likely buffer it from immediate rate or inflation shocks, while its performance might subtly signal shifts in healthcare spending patterns that precede broader economic trends.
For investors, AMGN's timing offers a significant lead time (6Q) to adjust for monetary policy shifts and inflation impacts. More notably, its -1Q lead on GDP and unemployment suggests AMGN could serve as an early-warning signal or a timely defensive allocation ahead of anticipated economic downturns, benefiting from its counter-cyclical characteristics. The response to GDP changes is transient (1Q half-life), while unemployment impacts persist moderately (3Q half-life).
In contrast to many companies that typically lag macroeconomic shifts, AMGN stands out by acting as a leading indicator for economic growth and labor market dynamics. While it exhibits a more conventional, albeit extended, lagging response to interest rates and inflation, its forward-looking correlation with GDP and unemployment underscores its distinct counter-cyclical characteristics in the market.
AMGN is positioned as a Mid-cycle company, which is consistent with its long lag to monetary policy and inflation, yet its leading indicator status for GDP and unemployment suggests a defensive, early-warning role within the broader economic cycle.
Company Timing Profiles
| Company | Rate Lag | CPI Lag | GDP Lag | Unemp Lag | Cycle Position |
|---|---|---|---|---|---|
| AMGN | 6Q | 6Q | -1Q | -1Q | Mid-cycle |
Lag = quarters after macro change before company fundamentals respond. Green = fast response (≤1Q). Red = slow response (≥4Q).
Cross-Correlation Analysis Results
Pearson correlation between company fundamentals (quarter-over-quarter changes) and macro variables at each lag. Highlighted cells indicate |r| ≥ 0.25 (significant).
AMGN
revenue_growth
Show correlation at all 13 lags
| Lag (Q) | -6 | -5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| r | -0.08 | -0.07 | -0.06 | -0.07 | -0.16 | -0.25 | -0.29 | -0.26 | -0.13 | 0.05 | 0.39 | 0.60 | 0.69 |
Yellow = optimal lag. Green/Red = significant positive/negative correlation.
AMGN shows strong positive correlation and responds 6 quarters after interest rate changes.
revenue_growth
Show correlation at all 13 lags
| Lag (Q) | -6 | -5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| r | 0.12 | 0.04 | 0.01 | -0.04 | -0.11 | -0.14 | -0.14 | -0.09 | -0.09 | -0.02 | 0.11 | 0.27 | 0.53 |
Yellow = optimal lag. Green/Red = significant positive/negative correlation.
AMGN shows strong positive correlation and responds 6 quarters after inflation changes.
revenue_growth
Show correlation at all 13 lags
| Lag (Q) | -6 | -5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| r | 0.06 | 0.24 | 0.14 | 0.07 | -0.05 | -0.26 | -0.10 | -0.06 | -0.02 | 0.12 | 0.04 | 0.09 | 0.24 |
Yellow = optimal lag. Green/Red = significant positive/negative correlation.
AMGN shows moderate negative correlation and moves 1 quarters before GDP growth changes.
revenue_growth
Show correlation at all 13 lags
| Lag (Q) | -6 | -5 | -4 | -3 | -2 | -1 | 0 | 1 | 2 | 3 | 4 | 5 | 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| r | -0.10 | -0.25 | -0.22 | -0.10 | 0.10 | 0.31 | 0.22 | 0.23 | 0.10 | -0.04 | 0.08 | 0.02 | -0.10 |
Yellow = optimal lag. Green/Red = significant positive/negative correlation.
AMGN shows moderate positive correlation and moves 1 quarters before unemployment changes.
Response Persistence
How long macro impacts persist after initial response.
| Company | Macro Variable | Peak Impact | Half-Life | Persistence |
|---|---|---|---|---|
| AMGN | RATES | 6Q | N/A | Unknown |
| AMGN | CPI | 6Q | N/A | Unknown |
| AMGN | GDP | -1Q | 1Q | Transient |
| AMGN | UNEMPLOYMENT | -1Q | 3Q | Moderate |
8G: Scenario Analysis & Stress Testing
This analysis delves into how specific macroeconomic scenarios could impact company fundamentals, providing a forward-looking perspective for institutional investors. We project changes in key performance metrics, such as revenue growth, under various stress conditions, leveraging sensitivity coefficients derived from Ridge regression analysis.
Our scenario framework encompasses four distinct macro environments: a benign Baseline, a 'Mild Stress' resembling early 2022, a 'Severe Stress' mirroring the 2008 Global Financial Crisis, and a 'Rate Shock' akin to the 2022 Fed tightening cycle. These scenarios are carefully constructed based on actual historical stress periods, not arbitrary assumptions, to offer relevant and robust stress testing.
AMGN
Amgen's revenue growth exhibits a notable 1.4 percentage point swing across macro scenarios, with a surprising resilience and even benefit under severe economic contraction, though projections carry low reliability.
Amgen's primary macroeconomic vulnerability is clearly rising interest rates, with a coefficient of -0.318. This means every 1.0pp increase in the Fed Funds rate could shave approximately 0.32pp off revenue growth. Rising inflation (coefficient -0.058) and falling GDP growth (coefficient 0.063, meaning a -1.0pp drop in GDP subtracts -0.063pp) also present headwinds, albeit to a lesser degree.
As only Amgen's stress profile is provided, a comprehensive cross-company comparison of resilience across the portfolio is not feasible at this juncture. However, Amgen's distinct sensitivities offer valuable insights into sector-specific macro exposures.
Historical Stress Periods (Reference)
Scenarios are calibrated to historical stress events. These periods inform the magnitude of macro assumptions.
| Period | Rates | CPI | GDP | Unemployment | S&P 500 |
|---|---|---|---|---|---|
|
2008 Financial Crisis
Sep 2008 - Mar 2009
|
-4.0pp | -4.5pp | -4.0pp | +5.0pp | -56.8% |
|
2020 COVID Crash
Feb 2020 - Apr 2020
|
-1.5pp | -1.5pp | -9.0pp | +11.0pp | -33.9% |
|
2022 Rate Tightening
Mar 2022 - Oct 2022
|
+4.2pp | +3.0pp | -0.5pp | +0.5pp | -25.4% |
Scenario Definitions
Baseline
BENIGNCurrent macro trajectory continues
| Interest Rates (Fed Funds) | No change |
| Inflation (CPI YoY) | No change |
| GDP Growth | No change |
| Unemployment Rate | No change |
Mild Stress
MILDModerate economic slowdown with rising rates
| Interest Rates (Fed Funds) | +1.0pp |
| Inflation (CPI YoY) | +1.0pp |
| GDP Growth | -1.0pp |
| Unemployment Rate | +1.0pp |
Severe Stress (2008-like)
SEVERESevere recession with deflationary pressures
| Interest Rates (Fed Funds) | -2.0pp |
| Inflation (CPI YoY) | -2.0pp |
| GDP Growth | -3.0pp |
| Unemployment Rate | +4.0pp |
Rate Shock (2022-like)
MODERATEAggressive rate tightening with persistent inflation
| Interest Rates (Fed Funds) | +2.0pp |
| Inflation (CPI YoY) | +2.0pp |
| GDP Growth | -0.5pp |
| Unemployment Rate | +0.5pp |
Company Stress Profiles
AMGN - Amgen Inc.
Show scenario-by-scenario breakdown
| Scenario | Total Impact | 95% CI | Reliability | Primary Driver |
|---|---|---|---|---|
| Baseline | +0.00pp | (+0.0, +0.0) | low | None identified |
| Mild Stress | -0.41pp | (-0.6, -0.2) | low | Interest Rates (Fed Funds) |
| Severe Stress (2008-like) | +0.66pp | (+0.3, +1.1) | low | Interest Rates (Fed Funds) |
| Rate Shock (2022-like) | -0.77pp | (-1.2, -0.4) | low | Interest Rates (Fed Funds) |
Analysis date: 2026-03-12 | Data as of: 2026-02-01
8H: Summary & Investment Implications
The current macro environment is characterized by an easing rate regime, with Fed Funds at 3.64%, and moderate inflation, with CPI YoY at 2.40%. This backdrop presents a mixed picture for the analyzed companies, necessitating a granular understanding of individual macro sensitivities and stress resilience to identify actionable investment strategies.
Macro Profile At a Glance
| Company | Macro Sensitivity | Regime Fit | Stress Resilience | Lowest Impact | Key Risk |
|---|---|---|---|---|---|
|
AMGN
Amgen Inc.
|
Moderate | Neutral | High |
-0.77pp
Rate Shock (2022-like)
|
cpi_falling |
Company Macro Assessments
Amgen (AMGN) exhibits moderate macro sensitivity and a neutral fit within the current easing rate and moderate inflation regime. Notably, the company demonstrates high stress resilience, suggesting a defensive profile that can withstand significant economic headwinds, though quantitative impact estimates should be interpreted with caution due to model limitations.
Investment Implications
Given AMGN's high stress resilience, notably a +0.66pp positive impact on Revenue Growth in a Severe Stress (2008-like) scenario, investors should consider an overweight position for defensive portfolio allocation. The company's ability to maintain or even improve performance during deep downturns makes it an attractive hedge against broader market volatility, despite its neutral fit in the current moderate inflation environment.
AMGN's key strength lies in rising CPI, while falling CPI is its primary risk factor. In a regime of moderate inflation (CPI YoY at 2.40%), this implies a neutral stance, but any upward shift in inflation could provide a tailwind. Conversely, a sustained deceleration in inflation would pose a direct challenge to the investment thesis, requiring careful monitoring.
Trading Considerations
Investors should closely monitor upcoming CPI data releases. Any indication of a sustained upward trend in inflation could serve as a bullish catalyst for AMGN, given its positive correlation with rising CPI.
Conversely, a clear deceleration in inflation below the current 2.40% YoY, particularly if approaching disinflationary or deflationary territory, would signal increasing macro headwinds for AMGN and warrant a re-evaluation.
While AMGN shows resilience, the -0.77pp impact in a Rate Shock (2022-like) scenario suggests that sudden, sharp interest rate hikes could still introduce short-term volatility, even if the current regime is easing.
Risk Watchlist
The primary macro risk for AMGN is a sustained decline in CPI. A fall below the current 2.40% YoY, particularly if it signals a broader deflationary trend, would trigger a reassessment of AMGN's macro positioning.
Although AMGN demonstrates high resilience, an extreme rate shock, mirroring the 2022 tightening cycle, could still negatively impact revenue growth by -0.77pp. Investors should watch for unexpected hawkish shifts in Fed policy or market rate expectations.
It is important to note that reliable quantitative estimates for macro sensitivities were not consistently available across all companies, including AMGN. Therefore, the stated stress impacts, while indicative, should be viewed with an understanding of this underlying model uncertainty.
Key Takeaways
- AMGN is a defensive play, demonstrating high resilience (+0.66pp in severe stress) against significant economic downturns.
- The company's performance is positively correlated with rising CPI, making inflation trends a critical watch factor.
- Current easing rates and moderate inflation provide a neutral macro backdrop for AMGN.
- Falling CPI represents the most significant macro risk, warranting close monitoring of inflation data.
- Quantitative impact estimates for AMGN should be interpreted with caution due to limitations in model reliability.